针对胰腺癌中MYC的概念。
Concepts to Target MYC in Pancreatic Cancer.
作者信息
Wirth Matthias, Mahboobi Siavosh, Krämer Oliver H, Schneider Günter
机构信息
II. Medizinische Klinik, Technische Universität München, München, Germany.
Institute of Pharmacy, Department of Pharmaceutical Chemistry I, Faculty of Chemistry and Pharmacy, University of Regensburg, Regensburg, Germany.
出版信息
Mol Cancer Ther. 2016 Aug;15(8):1792-8. doi: 10.1158/1535-7163.MCT-16-0050. Epub 2016 Jul 12.
Current data suggest that MYC is an important signaling hub and driver in pancreatic ductal adenocarcinoma (PDAC), a tumor entity with a strikingly poor prognosis. No targeted therapies with a meaningful clinical impact were successfully developed against PDAC so far. This points to the need to establish novel concepts targeting the relevant drivers of PDAC, like KRAS or MYC. Here, we discuss recent developments of direct or indirect MYC inhibitors and their potential mode of action in PDAC. Mol Cancer Ther; 15(8); 1792-8. ©2016 AACR.
目前的数据表明，MYC是胰腺导管腺癌（PDAC）中的一个重要信号枢纽和驱动因子，而PDAC是一种预后极差的肿瘤实体。到目前为止，尚未成功开发出对PDAC有显著临床影响的靶向疗法。这表明有必要建立针对PDAC相关驱动因子（如KRAS或MYC）的新概念。在此，我们讨论直接或间接MYC抑制剂的最新进展及其在PDAC中的潜在作用模式。《分子癌症治疗》；15(8)；1792 - 8。©2016美国癌症研究协会。
Zotero 插件